Literature DB >> 25086239

Adenosine receptor expression in a rat model of experimental autoimmune myasthenia gravis.

Na Li1, Geng Wang2, Xiuhua Yao3, Qingfei Kong3, Xiaoyu Shang3, Xiaoli Xie3, Jinghua Wang3, Xiaoying Kang3, Lianhong Jin4, Guangyou Wang3, Hulun Li3, Lili Mu5, Bo Sun6.   

Abstract

Extracellular adenosine is an essential negative regulator of immune reactions that acts by signaling via 4 distinct adenosine receptors. We evaluated adenosine receptor expression in Lewis rats presenting with experimental autoimmune myasthenia gravis (EAMG) to determine whether the expression of adenosine receptors are changed in the development and progression of EAMG. Lymphocyte A1AR and A2AAR mRNA and protein levels from lymphocytes harvested from the lymph nodes, spleen, and peripheral blood mononuclear cells (PBMCs) of EAMG rats were decreased. A modest but not significant increase in A2BAR levels was observed in EAMG lymphocytes harvested from lymph nodes and PBMCs. No changes in A3AR expression were observed in lymphocytes harvested from lymph nodes, spleen, or PBMCs following EAMG induction. Results presented in this report showed that the expression levels and the distribution pattern of adenosine receptors were altered in EAMG lymphocytes.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AChR; Adenosine receptor; Autoimmune disease; EAMG

Mesh:

Substances:

Year:  2014        PMID: 25086239     DOI: 10.1016/j.cellimm.2014.07.005

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

Review 1.  Animal models of myasthenia gravis: utility and limitations.

Authors:  Renato Mantegazza; Chiara Cordiglieri; Alessandra Consonni; Fulvio Baggi
Journal:  Int J Gen Med       Date:  2016-03-04

Review 2.  The role of adenosinergic pathway in human autoimmune diseases.

Authors:  Ke Dong; Zhao-Wei Gao; Hui-Zhong Zhang
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.